The politics of health technology assessment in Poland

Piotr Ozieranski, Martin McKee and Lawrence King

Health Policy, 2012, vol. 108, issue 2, 178-193

Abstract: First, to identify risks associated with the scientific evaluation of drugs considered for state reimbursement in Poland through exploring strategies of influence employed by multinational drug companies in relation to the Agency for Health Technology Assessment (AHTAPol). Second, to ascertain whether the outcomes of drug evaluation meet the interests of the public payer in reimbursing cost-effective drugs supported by robust pharmacoeconomic evidence.

Keywords: Health technology assessment; Pharmaceutical industry; Medical experts; Key opinion leaders; Patient organisations; Poland; Conflicts of interest; Coincidences of interest; Drug reimbursement (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851012002825
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:108:y:2012:i:2:p:178-193

DOI: 10.1016/j.healthpol.2012.10.001

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().